• English
  • Deutsch
  • Log In
    Password Login
    Research Outputs
    Fundings & Projects
    Researchers
    Institutes
    Statistics
Repository logo
Fraunhofer-Gesellschaft
  1. Home
  2. Fraunhofer-Gesellschaft
  3. Artikel
  4. Cardio-Hepatic Interaction in Cardiac Amyloidosis
 
  • Details
  • Full
Options
2024
Journal Article
Title

Cardio-Hepatic Interaction in Cardiac Amyloidosis

Abstract
Background: Congestion is associated with poor prognosis in cardiac amyloidosis (CA). The cardio-hepatic interaction and the prognostic impact of secondary liver affection by cardiac congestion in CA are poorly understood and require further characterisation.
Methods: Participants of the amyloidosis cohort study AmyKoS at the Interdisciplinary Amyloidosis Centre of Northern Bavaria with proven transthyretin (ATTR-CA) and light chain CA (AL-CA) underwent serial work-up including laboratory tests, echocardiography, and in-depth hepatic assessment by vibration-controlled transient elastography (VCTE) and 13C-methacetin breath test.
Results: In total, 74 patients with AL-CA (n = 17), ATTR-CA (n = 26) and the controls (n = 31) were analysed. ATTR-CA patients showed decreased microsomal liver function expressed by maximal percentage of dose rate (PDRpeak) related to hepatic congestion. Reduced PDRpeak in AL-CA could result from altered pharmacokinetics due to changed hepatic blood flow. Liver stiffness as a combined surrogate of chronic liver damage and congestion was identified as a predictor of all-cause mortality. Statistical modelling of the cardio-hepatic interaction revealed septum thickness, NT-proBNP and PDRpeak as predictors of liver stiffness in both CA subtypes; dilatation of liver veins and the fibrosis score FIB-4 were only significant for ATTR-CA.
Conclusions: Non-invasive methods allow us to characterise CA-associated hepatic pathophysiology. Liver stiffness might be promising for risk stratification in CA.
Author(s)
Ihne-Schubert, Sandra Michaela
Universitätsklinikum Würzburg, Interdisziplinäres Amyloidosezentrum Nordbayern
Goetze, Oliver
Universitätsklinikum Würzburg, Interdisziplinäres Amyloidosezentrum Nordbayern
Gerstendörfer, Felix
Universitätsklinikum Würzburg, Interdisziplinäres Amyloidosezentrum Nordbayern
Sahiti, Floran
Universitätsklinikum Würzburg, Interdisziplinäres Amyloidosezentrum Nordbayern
Schade, Ina
Helios Klinikum Erfurt, Thoraxchirurgie und thorakale Endoskopie
Papagianni, Aikaterini
Universitätsklinikum Würzburg, Interdisziplinäres Amyloidosezentrum Nordbayern
Morbach, Caroline
Universitätsklinikum Würzburg, Interdisziplinäres Amyloidosezentrum Nordbayern
Frantz, Stefan
Universitätsklinikum Würzburg, Interdisziplinäres Amyloidosezentrum Nordbayern
Einsele, Hermann
Universitätsklinikum Würzburg, Interdisziplinäres Amyloidosezentrum Nordbayern
Knop, Stefan
Universitätsklinikum Würzburg, Interdisziplinäres Amyloidosezentrum Nordbayern
Sommer, Claudia
Universitätsklinikum Würzburg, Interdisziplinäres Amyloidosezentrum Nordbayern
Müllhaupt, Beat
Universitätsspital Zürich, Klinik für Gastroenterologie und Hepatologie
Störk, Stefan
Universitätsklinikum Würzburg, Interdisziplinäres Amyloidosezentrum Nordbayern
Schubert, Torben  orcid-logo
Fraunhofer-Institut für System- und Innovationsforschung ISI  
Geier, Andreas
Universitätsklinikum Würzburg, Interdisziplinäres Amyloidosezentrum Nordbayern
Journal
Journal of Clinical Medicine  
Open Access
DOI
10.3390/jcm13051440
10.24406/publica-2903
File(s)
Ihne-Schubert_2024_Cardio-Hepatic_Interaction_in_Cardiac_ Amyloidosis.pdf (1.46 MB)
Rights
CC BY 4.0: Creative Commons Attribution
Language
English
Fraunhofer-Institut für System- und Innovationsforschung ISI  
Keyword(s)
  • Cardiac amyloidosis

  • 13C-methacetin breath test (MBT)

  • Liver stiffness

  • Vibration-controlled transient elastography (VTCE)

  • PDR

  • Congestion

  • Cookie settings
  • Imprint
  • Privacy policy
  • Api
  • Contact
© 2024